Exenatide lowered protein-based age scores in people
Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.

Our read
Interventions- Studied:
- Randomized trial in 3,973 people with type 2 diabetes, 12 months, against placebo (Placebo-controlled)
- What changed:
- Exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo
- The catch:
- Only participants with blood samples at both time points were included
- In the record:
- The 44th paper on exenatide with results in people; 228 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
People with type 2 diabetes—3,973 participants in a randomized trial—had blood samples analyzed at the start and 12 months later. The trial compared once-weekly exenatide with placebo. Researchers measured 4,979 blood proteins to calculate an overall biological age score and 11 scores based on proteins associated with particular organs.
Six scores fell with exenatide: those linked to the heart, pancreas, brain, arteries, fat tissue and muscle. The liver score rose less than with placebo. Gaps between protein-based age and age in years were also associated with later major cardiovascular events and hospitalization for heart failure. The heart aging score showed the strongest treatment effects and links to future cardiovascular risk.
Why it matters
The authors suggest that protein-based measures of organ aging may serve as markers of treatment response and targets for future therapies.
Caveats
Protein-based age scores are indirect measures; changes do not by themselves show better organ function or longer life. The analysis included only participants with blood samples at both time points and was reported as a conference abstract.
The paper
GLP-1 Receptor Agonism Slows Biologic Clocks Across Multiple Organs
Duke University
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 6023




Comments
Be the first to comment.